New potential targets for treatment of Cushing’s disease: epithelial growth factor receptor and cyclin-dependent kinases

摘要: Background Cushing’s disease (CD) is caused by adrenocorticotropic hormone (ACTH)-producing pituitary adenomas (ACTHomas). Drug treatment for CD consists of three strategies: tumor-targeted therapy, steroidogenesis inhibitors, and glucocorticoid receptor antagonists. All these strategies are under development, several new drugs have recently been approved clinical use or being tested in trials. Pituitary-targeted a particularly important method the CD. Available include dopamine agonist somatostatin analog. Since disrupted cell cycle signaling clearly associated with pathogenesis ACTHomas which express active forms epithelial growth factor (EGFR), cyclins, catalytic subunit cyclin-dependent kinases (CDKs), we focused on molecules as therapeutic targets ACTHomas. Methods In this review, literature search were performed using PubMed following terms; disease, EGFR, CDKs, cycle, targeted therapy. Conclusion Accumulating evidence demonstrates that EGFR cyclin E-CDK2 may be promising treating